Aurora Cannabis (ACB) Q3 2026 earnings review
Pure-Play Medical Pivot Delivers Cash, Sheds Weight
Aurora Cannabis is decisively exiting the volatility of consumer cannabis to becoming a pure-play medical operator. Q3 delivered $94.2M in revenue (+7% YoY), driven by a robust Medical segment that now commands 81% of total sales with a towering 69% gross margin. The company generated $15.5M in Free Cash Flow—a rarity in the sector. Concurrently, Aurora announced the spin-out of its troubled Bevo plant propagation unit and a further exit from lower-margin consumer markets. While the $100M ATM filing raises dilution eyebrows given the strong cash position, the operational core is stabilizing.
🐂 Bull Case
Medical Cannabis revenue grew 12% YoY to $76.2M, maintaining an industry-leading 69% adjusted gross margin. With 90% of capacity GMP-certified, Aurora holds a structural advantage in high-barrier international markets (Germany, Poland, Australia).
Aurora generated $15.5M in Free Cash Flow this quarter, a significant turnaround from typical sector cash burn. With $108M in liquid cash/investments and a debt-free cannabis division, the balance sheet is a fortress compared to peers.
🐻 Bear Case
The non-medical segments are imploding. Consumer cannabis revenue fell 48% YoY to just $5.2M. Bevo (Plant Propagation) margins collapsed to 16% (from 40% YoY) due to inventory write-offs, necessitating a complex spin-out transaction.
Despite boasting about a strong cash position and positive FCF, management filed a new $100M USD ATM program. This signals potential large-scale M&A or a lack of confidence in sustaining organic cash generation.
⚖️ Verdict: 🟢
Bullish. The strategic clarity is refreshing. By amputating the bleeding Consumer and Bevo limbs, Aurora reveals a highly profitable, cash-generative Medical core. If they execute the Bevo spin-out cleanly, the remaining entity is the highest-quality asset in Canadian cannabis.
Key Themes
International Medical Expansion
Accelerating. International medical revenue reached $48.0M, up 17% YoY and 12% sequentially. The segment is benefiting from the German de-scheduling and growth in Australia/UK. This is the highest margin revenue stream in the company, driving the consolidated adjusted gross margin to 62%.
Bevo Margin Implosion & Exit
Reversing. Bevo (Plant Propagation) went from a diversifier to a liability. Adjusted gross margins collapsed from 40% in 25Q3 to just 16% in 26Q3 due to inventory write-offs and labor costs. Management is exchanging its common shares for preferred shares to de-consolidate Bevo—effectively admitting the diversification strategy failed.
The $100M ATM Disconnect
Management highlights $108M in liquidity and positive Free Cash Flow, yet simultaneously filed a $100M USD At-The-Market equity program. This contradicts the 'self-sustaining' narrative and implies shareholder dilution is imminent, likely for M&A given the stated 'strategic purposes' rationale.
Cost Discipline & EBITDA Stability
Stable. Adjusted SG&A of $35.8M was relatively flat sequentially. Adjusted EBITDA of $18.5M (20% margin) shows operational maturity. With the planned exit of lower-margin consumer markets in Q4, management guides for further SG&A reductions, protecting the bottom line.
Other KPIs
Stable. Down slightly from $19.4M YoY but up 20% sequentially from $15.4M in Q2. Ninth consecutive quarter of positive EBITDA, demonstrating the stability of the medical-first model.
Reversing. A massive swing from a $42.3M outflow in Q2 to a $15.5M inflow in Q3. This was driven by a $10.9M working capital recovery and strong operational cash flow. It validates the company's claim of financial sustainability.
Decelerating. Revenue nearly halved YoY (-48%). This segment is being actively managed for exit/optimization. Margins here are 28% vs Medical's 69%, making the revenue loss accretive to the overall margin profile.
Guidance
Accelerating. Management expects EBITDA improvements in coming quarters following the exit of low-margin consumer markets.
Decelerating. The exit from consumer markets will incur non-recurring costs in Q4, likely impacting cash flow temporarily before stabilizing.
Stable/Accelerating. Management continues to prioritize allocation of product to high-margin global medical channels, expecting continued growth.
Key Questions
ATM Utilization
With positive Free Cash Flow and over $100M in liquidity, why is the $100M ATM necessary immediately? Is a specific acquisition target imminent?
Bevo Spin-out Mechanics
Regarding the Bevo exchange for preferred shares: What is the expected valuation impact on the balance sheet, and will the 5% dividend on preferreds actually be paid given Bevo's recent covenant breaches?
Consumer Exit Costs
What is the total estimated cash cost of restructuring/exiting the specific consumer markets in Q4, and will this result in material inventory write-downs?